Pathogenetic factors and pharmacotherapy of gastroesophageal reflux disease

Chinese Journal of Gastroenterology

Volumn 13, Issue 11, 2008, Pages 696-698

  Fang, Li ^a   Meng, Lina ^a  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Drug therapy; Gastroesophageal reflux etiology; Gastroesophageal reflux therapy

Indexed keywords

EID: 79952550473     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Vakil N, van Zanten SV, Kahrilas P, et al. Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol, 2006, 101 (8): 1900-1920.
2. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut, 2005, 54 (5): 710-717. (Pubitemid 40559260)
3. Wong BC, Kinoshita Y. Systematic review on epidemiology of gastroesophageal reflux disease in Asia. Clin Gastroenterol Hepatol, 2006, 4 (4): 398-407.
4. Chen M, Xiong L, Chen H, et al. Prevalence, risk factors and impact of gastroesophageal reflux disease symptoms: a population-based study in South China. Scand J Gastroenterol, 2005, 40 (7): 759-767. (Pubitemid 40978850)
5. Moss SF, Armstrong D, Arnold R, et al. GERD 2003 - a consensus on the way ahead. Digestion, 2003, 67 (3): 111-117. (Pubitemid 36829075)
6. Oman TI, Barnett CP, Benninga MA, et al. Mechanisms of gastro-oesophageal reflux in preterm and term infants with reflux disease. Gut, 2002, 51 (4): 475-479.
7. Wong WM, Lai KC, Hui WM, et al. Pathophysiology of gastroesophageal reflux diseases in Chinese -role of transient lower esophageal sphincter relaxation and esophageal motor dysfunction. Am J Gastroenterol, 2004, 99 (11): 2088-2093. (Pubitemid 39524695)
8. Rossiter A, Guelrud M, Souney PF, et al. High vasoactive intestinal polypeptide plasma levels in patients with Barrett's esophagus. Scand J Gastroenterol, 1991, 26 (5): 572-576.
9. Shafik A, Ahmed I, El Sibai O, et al. Interstitial cells of cajal in reflux esophagitis: role in the pathogenesis of the disease. Med Sci Monit, 2005, 11 (12): BR452-BR456. (Pubitemid 43138416)
10. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol, 2005, 100 (1): 190-200. (Pubitemid 41623288)
11. Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol, 2004, 19 (4): 357-367. (Pubitemid 38570184)
12. Miner P Jr, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. Am J Gastroenterol, 2002, 97 (6): 1332-1339. (Pubitemid 34664773)
13. Michael FV. Ear, nose, and throat manifestations of gastroesophageal reflux disease. Clin Perspect Gastroenterol, 2002, 5: 324-328.
14. Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol, 2003, 98 (3): 545-550. (Pubitemid 36348523)
15. Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut, 2003, 52 (4): 464-470. (Pubitemid 36367205)
16. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodenogastro-oesophageal reflux refractory to proton pump inhibitors. Gut, 2003, 52 (10): 1397-1402. (Pubitemid 37176716)